Regeneron Pharmaceuticals, Inc. (REGN) Easily Tops Q1 EPS Views

May 3, 2013 6:33 AM EDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $1.78, versus the analyst estimate of $1.46. Revenue for the quarter came in at $440 million versus the consensus estimate of $424.26 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Hot Earnings

Related Entities

Earnings